Corvus Pharmaceuticals (CRVS) Operating Income (2015 - 2026)

Corvus Pharmaceuticals' Operating Income history runs 12 years deep, the most recent figure standing at -$14.9 million for Q1 2026.

• In Q1 2026, Operating Income fell 49.94% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$45.6 million (down 55.39% YoY), while the FY2023 annual figure was -$23.4 million, up 28.12% from the prior year.
• Operating Income for Q1 2026 stood at -$14.9 million, down from -$10.6 million in the prior quarter.
• The five-year high for Operating Income was -$5.6 million in Q3 2023, with the low at -$14.9 million in Q1 2026.
• The 5-year median for Operating Income is -$7.0 million (2022), against an average of -$8.1 million.
• The sharpest annual moves came in 2023 and 2025: Operating Income surged 55.42% in 2023, then plunged 72.87% in 2025.
• Corvus Pharmaceuticals' Operating Income stood at -$5.7 million in 2022, then climbed by 0.26% to -$5.7 million in 2023, then decreased by 28.38% to -$7.3 million in 2024, then plunged by 45.72% to -$10.6 million in 2025, then slumped by 40.72% to -$14.9 million in 2026.
• Business Quant data shows CRVS's Operating Income at -$14.9 million in Q1 2026, -$10.6 million in Q3 2025, and -$10.3 million in Q2 2025.